Prothiaden
Prothiaden Price range: $ 32,00 through $ 131,00
Back to products
Provera
Provera Price range: $ 14,00 through $ 265,00

Protonix

Price range: $ 19,00 through $ 217,00

Protonix is a highly effective proton pump inhibitor designed to provide lasting relief from frequent heartburn and acid reflux symptoms. By reducing the amount of acid produced in the stomach, this medication helps heal the lining of the esophagus from damage caused by gastric acid. It is widely used for the long-term management of gastroesophageal reflux disease (GERD) to prevent recurring symptoms and discomfort. Additionally, Protonix is indicated for treating hypersecretory conditions such as Zollinger-Ellison syndrome, where the stomach produces an excessive amount of acid. These delayed-release tablets offer consistent and reliable support for individuals seeking to improve their digestive comfort and overall esophageal health.

Active substance: Pantoprazole
SKU: Protonix Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Protonix – Information for Patients and Caregivers

Protonix belongs to a class of therapeutic agents known as proton pump inhibitors (PPIs). The medication contains the active substance pantoprazole sodium and is indicated for the treatment of acid-related gastrointestinal conditions under federal prescription regulations in the United States.

This drug is prescribed primarily for the short-term healing and symptomatic relief of erosive esophagitis associated with gastroesophageal reflux disease, as well as long-term management of pathological hypersecretory conditions. The administration of this formulation requires formal medical evaluation and a prescription from a licensed healthcare provider.

Active Ingredient Pantoprazole sodium
Therapeutic Class Proton pump inhibitor (PPI)
Dosage Forms Oral delayed-release tablets (20 mg, 40 mg); Oral granules; Intravenous injection
Prescription Status Prescription only (Rx)
Primary Purpose Gastric acid suppression and mucosal healing
Storage Conditions Controlled room temperature 20°C to 25°C (68°F to 77°F)

How the drug works

The active compound, pantoprazole sodium, operates as a substituted benzimidazole that suppresses gastric acid secretion through targeted enzyme inhibition. Specifically, it functions by irreversibly binding to the (H+, K+)-ATPase enzyme system, commonly referred to as the proton pump, located on the secretory surface of gastric parietal cells. By inhibiting this final step in the acid secretion cascade, the medication effectively decreases both basal and stimulated gastric acid production, regardless of the primary stimulus.

The antisecretory effect of pantoprazole is concentration-dependent and leads to an elevation of intragastric pH. The duration of acid suppression persists beyond the presence of the drug in systemic circulation due to the covalent binding to the proton pump enzyme complex, requiring new enzyme synthesis to restore baseline acid secretion.

Main uses

The primary FDA-approved indication for Protonix delayed-release tablets is the short-term treatment (typically up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis associated with gastroesophageal reflux disease (GERD) in adults and pediatric patients aged 5 years and older. Additionally, it is approved for the maintenance of healing of erosive esophagitis and reduction in relapse rates of heartburn symptoms in adult patients.

Another primary indication includes the long-term management of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. Clinical applications not explicitly listed in the official labeling, such as prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced gastric ulcers or stress ulcer prophylaxis in critically ill individuals, represent off-label uses and must be evaluated on an individual basis by a qualified clinician.

Dosing schedule

Dosage regimens are individualized based on the specific clinical indication and patient profile. For the treatment of erosive esophagitis in adult patients, the standard recommended oral dosage is 40 mg taken once daily for a period of up to 8 weeks. For maintenance of healing of erosive esophagitis, the typical adult dosage is 40 mg once daily.

For pathological hypersecretory conditions such as Zollinger-Ellison syndrome, the initial starting dose for adult patients is typically 40 mg twice daily, with subsequent adjustments titrated up to 240 mg daily depending on clinical response and gastric acid output measurement. Tablets must be swallowed whole with fluid and should not be split, crushed, or chewed, as doing so compromises the enteric coating designed to prevent premature drug degradation in gastric acid.

What happens in the body

Following oral administration of pantoprazole delayed-release tablets, absorption occurs within the small intestine after the tablet leaves the stomach intact. Peak plasma concentration (Cmax) is generally reached approximately 2 to 2.5 hours post-dose. The absolute oral bioavailability of pantoprazole from the delayed-release tablet formulation is approximately 77%, remaining consistent regardless of single or multiple dosing.

Pantoprazole undergoes extensive hepatic metabolism primarily mediated by the cytochrome P450 enzyme CYP2C19, with secondary metabolism via CYP3A4. The terminal elimination half-life of pantoprazole is approximately 1 hour in individuals with normal metabolic function. Approximately 71% to 80% of the administered dose is excreted in the urine as metabolic derivatives, while the remainder is eliminated via the biliary-fecal route. Serum protein binding is approximately 98%, predominantly to plasma albumin.

What not to combine

Pantoprazole can alter the absorption of medications whose bioavailability is pH-dependent due to its potent and long-lasting inhibition of gastric acid secretion. Concomitant administration of pantoprazole with antiretroviral therapies such as atazanavir or nelfinavir is generally contraindicated, as lowered gastric acidity significantly reduces plasma concentrations of these antiviral agents, potentially leading to therapeutic failure.

Co-administration with drugs such as ketoconazole, itraconazole, or iron salts may result in impaired absorption of these agents. Patients receiving concomitant warfarin therapy require monitoring of International Normalized Ratio (INR) and prothrombin time due to potential risks of increased INR. Furthermore, high-dose methotrexate co-administered with proton pump inhibitors may elevate and prolong serum levels of methotrexate and its metabolite, increasing the potential for toxicity.

What side effects may occur

Clinical trials and post-marketing surveillance indicate that pantoprazole is generally tolerated, though adverse effects may occur. The most commonly reported clinical adverse reactions in adult trials include headache, diarrhea, nausea, abdominal pain, flatulence, vomiting, dizziness, and arthralgia. In pediatric populations, adverse events such as upper respiratory tract infection and pyrexia are also noted.

Extended administration of proton pump inhibitors has been associated with class-specific adverse profiles. Prolonged therapy (exceeding 3 years) may impair intestinal absorption of cyanocobalamin (vitamin B12), leading to deficiency. Additional potential risks associated with chronic use include hypomagnesemia, elevated risk of Clostridium difficile-associated diarrhea, and increased risk of osteoporosis-related fractures of the hip, wrist, or spine during high-dose, long-term therapy.

Red flags

Immediate medical evaluation is necessary if signs of severe systemic or hypersensitivity reactions manifest during treatment. Critical clinical observations requiring urgent intervention include signs of anaphylaxis, such as swelling of the face, lips, tongue, or throat, alongside severe dyspnea or swallowing difficulties. The appearance of widespread cutaneous reactions, including bullous eruptions, skin peeling, or Stevens-Johnson syndrome, demands immediate drug discontinuation and acute care.

Additionally, patients presenting with severe, watery diarrhea accompanied by persistent abdominal cramping and fever should be evaluated for Clostridium difficile infection. Symptoms indicative of severe hypomagnesemia–such as muscle spasms, tremors, tetany, cardiac arrhythmias, or seizures–warrant prompt medical monitoring and laboratory assessment of serum electrolyte levels.

Important precautions

Symptomatic response to pantoprazole therapy does not preclude the presence of gastric malignancy; appropriate diagnostic evaluation should be conducted if alarm symptoms such as unexpected weight loss, recurrent vomiting, or melena occur. Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs, with onset ranging from weeks to years following initiation of therapy.

Acute tubulointerstitial nephritis has been observed in patients taking proton pump inhibitors and may occur at any point during therapy. In pregnant women, pantoprazole should be used only if the potential benefit justifies the potential risk to the fetus, as adequate and well-controlled clinical studies in pregnant human subjects are limited. Pantoprazole is excreted in human milk; decision-making regarding nursing vs. drug administration must weigh maternal clinical necessity.

What to avoid while taking it

Pantoprazole delayed-release tablets may be administered with or without food. However, administration prior to a meal (typically 30 minutes before breakfast) is frequently recommended in clinical protocols to align peak systemic exposure with parietal cell activation. Alcohol does not exhibit a direct pharmacokinetic interaction with pantoprazole, but ethanol ingestion can directly irritate the gastric mucosa and exacerbate underlying acid reflux symptoms, compromising overall therapeutic outcomes.

If you skip a dose

If a dose of pantoprazole is omitted, the missed dose should be taken as soon as remembered on the same day, provided the time for the next scheduled dose is not near. If the time is close to the next scheduled administration, the missed dose should be skipped entirely, resuming the standard dosing schedule. Under no circumstances should double doses be taken concurrently to compensate for an omitted administration.

Storage and expiration

Protonix delayed-release tablets should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F) in accordance with USP standards. The product must be protected from light and moisture, kept in its original container, and maintained out of reach of children. Expired medications should be disposed of in compliance with federal and state waste disposal guidelines.

Q&A

How long does it take for pantoprazole to demonstrate clinical efficacy?
Initial reduction in gastric acid secretion occurs within 2.5 hours following single-dose administration; however, complete symptomatic relief of acid reflux or healing of esophageal lesions typically requires continuous daily treatment over several days to weeks.

Can pantoprazole tablets be dissolved or crushed for easier administration?
No, pantoprazole delayed-release tablets must be swallowed whole. Crushing, chewing, or splitting the tablet damages the enteric coating, leading to drug degradation by stomach acid before reaching the site of intestinal absorption.

What laboratory monitoring is advised during long-term therapy?
For patients maintained on long-term pantoprazole, clinicians may periodically monitor serum magnesium levels prior to initiation and periodically thereafter, as well as serum cyanocobalamin (vitamin B12) levels and bone density status in patients with elevated fracture risk.

Is abrupt cessation of pantoprazole associated with rebound acid hypersecretion?
Discontinuation of prolonged proton pump inhibitor therapy can lead to transient rebound acid hypersecretion, where acid production temporarily increases above baseline. Tapering the dosage under clinical supervision may be recommended when discontinuing long-term treatment.

Does pantoprazole interact with routine blood testing?
Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. Elevated CgA levels may cause false-positive diagnostic results for neuroendocrine tumors; therapy should be temporarily stopped at least 14 days prior to CgA testing.

In accordance with FDA requirements.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

20 mg

,

40mg

Package

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία